Recentive Analytics, Inc., v. Fox Corp., Appeal No. 2023-2437 (Fed. Cir. Apr. 18, 2025)
In our Case of the Week, the Federal Circuit addressed a question of first impression concerning whether developments in machine...more
4/22/2025
/ Algorithms ,
Alice/Mayo ,
Appeals ,
Artificial Intelligence ,
Innovative Technology ,
Intellectual Property Litigation ,
Inter Partes Review (IPR) Proceeding ,
Machine Learning ,
Patent Invalidity ,
Patent Litigation ,
Patent-Eligible Subject Matter ,
Patents ,
Prior Art ,
Section 101
Azurity Pharmaceuticals, Inc. v. Alkem Laboratories Ltd., Appeal No. 2023-1977 (Fed. Cir. Apr. 8, 2025)
In our Case of the Week, the Federal Circuit affirmed that defendant Alkem’s proposed generic antibiotic did not...more
4/15/2025
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Claim Construction ,
Generic Drugs ,
Hatch-Waxman ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Pharmaceutical Industry ,
Pharmaceutical Patents ,
Prior Art ,
Writ of Mandamus
In re Forest, Appeal No. 2023-1178 (Fed. Cir. Apr. 3, 2025)
In an appeal from a Patent Office decision denying a patent that would have been expired upon issuance, the Federal Circuit dismissed. Applicant Forest had filed...more
In re: Riggs, Appeal No. 2022-1945 (Fed. Cir. Mar. 24, 2025)
Our Case of the Week explores the power of an examiner to request a rehearing after the Board has entered a decision on an application. The case also relates to...more
4/1/2025
/ America Invents Act ,
Appeals ,
Claim Construction ,
Damages ,
Intellectual Property Protection ,
Judicial Authority ,
Obviousness ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art ,
Remand ,
USPTO ,
Vacated
Actavis Labs. FL, Inc. v. United States, Appeal No. 2023-1320 (Fed. Cir. Mar. 21, 2025)
Our Case of the Week, in the words of its author, Circuit Judge Stark, “is not actually a patent case. It is, instead, a tax case.” In...more
3/25/2025
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Claim Construction ,
Court of Federal Claims ,
Food and Drug Administration (FDA) ,
Generic Drugs ,
Hatch-Waxman ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
USPTO
In re: Xencor, Inc., Appeal No. 2024-1870 (Fed. Cir. Mar. 13, 2025)
Our case of the week is an appeal from a decision of the Appeals Review Panel of the Patent Trial and Appeal Board, concerning Xencor’s patent application...more
3/18/2025
/ Appeals ,
Claim Construction ,
Federal Court Litigation ,
Intellectual Property Protection ,
Life Sciences ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Reissue Patents ,
Written Descriptions
Apple Inc. v. Gesture Technology Partners, LLC, Appeal Nos. 2023-1475, -1533 (Fed. Cir. Mar. 4, 2025)
Our Case of the Week is a high-stakes appeal from an inter partes review concerning a patent titled “Camera Based...more
3/11/2025
/ Appeals ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Obviousness ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Remand ,
Technology ,
USPTO ,
Vacated
After an inter partes review finds certain claims of a patent unpatentable, may the patentee assert other claims, immaterially different, in district court without being collaterally estopped? This was the question presented...more
2/18/2025
/ Abstract Ideas ,
Administrative Law Judge (ALJ) ,
Appeals ,
Discovery ,
Final Written Decisions ,
Intellectual Property Litigation ,
Inter Partes Review (IPR) Proceeding ,
International Trade Commission (ITC) ,
Motion to Dismiss ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents
Trudell Medical International Inc. v. D R Burton Healthcare, LLC, Appeal Nos. 2023-1777, -1779 (Fed. Cir. Feb. 7, 2025)
This week’s Case of the Week presents a cautionary tale for litigators to be sure they’ve timely...more
Regeneron Pharmaceuticals, Inc. v. Mylan Pharmaceuticals Inc., Appeal Nos. 2024-1965, -1966, -2082, -2083 (Fed. Cir. Jan. 29, 2025)
Our Case of the Week is a 31-page decision that touches on a variety of issues, including...more
2/4/2025
/ Appeals ,
Biologics ,
Cross-Appeals ,
Food and Drug Administration (FDA) ,
Intellectual Property Litigation ,
Inter Partes Review (IPR) Proceeding ,
Jurisdiction ,
Obviousness ,
Obviousness-Type Double Patenting (ODP) ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Preliminary Injunctions ,
Section 112 ,
Written Descriptions
Steuben Foods, Inc. v. Shibuya Hoppman Corp., Appeal No. 2023-1790 (Fed. Cir. Jan. 24, 2025)
In its only precedential patent decision this week, the Federal Circuit addressed an “anachronistic exception, long mentioned but...more
1/29/2025
/ Appeals ,
Claim Construction ,
Damages ,
Doctrine of Equivalents ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
JMOL ,
Patent Act ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Summary Judgment
Bearbox LLC v. Lancium LLC, Appeal No. 2023-1922 (Fed. Cir. Jan. 13, 2025)
In this week’s Case of the Week, the Federal Circuit affirmed a district court’s determination that appellants Bearbox and Austin Storms—Bearbox’s...more
1/23/2025
/ Appeals ,
Appellate Courts ,
Intellectual Property Litigation ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Inventions ,
Inventors ,
Obviousness ,
Patent Applications ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Prior Art
In re Entresto (Sacubitril/Valsartan), Appeal Nos. 2023-2218, -2220, -2221 (Fed. Cir. Jan. 10, 2025)
In our Case of the Week, the Federal Circuit revived Novartis’s US Patent No. 8,101,659 by reversing the district...more
Honeywell International Inc. v. 3G Licensing, S.A., Appeal Nos. 2023-1354, -1384, -1407 (Fed. Cir. Jan. 2, 2025)
In this week’s Case of the Week, the Federal Circuit reversed an inter partes review finding of the Patent...more
CloudofChange, LLC v. NCR Corp., Appeal No. 2023-1111 (Fed. Cir. Dec. 18, 2024)
In our Case of the Week, the Federal Circuit addressed the question of divided infringement in the context of system claims. In its...more
12/24/2024
/ Abbreviated New Drug Application (ANDA) ,
Appeals ,
Claim Construction ,
Food and Drug Administration (FDA) ,
Hatch-Waxman ,
Inter Partes Review (IPR) Proceeding ,
Motivation to Combine ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Patents ,
Remand ,
Reversal ,
Technology ,
Vacated
DDR Holdings, LLC v. Priceline.com LLC, Appeal Nos. 2023-1176, -1177 (Fed. Cir. Dec. 9, 2024)
In our Case of the Week, the Federal Circuit affirmed a stipulated non-infringement judgment from Delaware’s district court,...more
12/17/2024
/ America Invents Act ,
Appeals ,
Claim Construction ,
Inter Partes Review (IPR) Proceeding ,
Inventions ,
Noninfringement ,
On-Sale Bar ,
Patent Infringement ,
Patent Litigation ,
Patents ,
Remand ,
Reversal
Mirror Worlds Technologies, LLC v. Meta Platforms, Inc., Appeal Nos. 2022-1600, -1709 (Fed. Cir. Dec. 4, 2024)
In this appeal from the United States District Court for the Southern District of New York, the Federal...more
12/10/2024
/ Appeals ,
Cross-Appeals ,
Doctrine of Equivalents ,
En Banc Review ,
Generic Drugs ,
Inter Partes Review (IPR) Proceeding ,
Noninfringement ,
Obviousness ,
Patent Infringement ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Pharmaceutical Industry ,
Summary Judgment ,
Technology
Cisco Systems, Inc. et al. v. K.Mizra LLC, Appeal Nos. 2022-2290, 2023-1183 (Fed. Cir. Nov. 19, 2024)
In the Federal Circuit’s only precedential action this week, a panel of the Court declined to dismiss an appeal after...more
Telefonaktiebolaget LM Ericsson, Ericsson AB, Ericsson, Inc. v. Lenovo (United States), Inc. et. al., Appeal No. 2024-1515 (Fed. Cir. Oct. 24, 2024)
In our Case of the Week, the Federal Circuit clarified that, for an...more
UTTO Inc. v. Metrotech Corp., Appeal No. 23-1435 (Fed. Cir. Oct. 18, 2024)
In its only precedential patent decision this week, the Court analyzed the extent to which claim construction is appropriate on a motion to...more
AlexSam, Inc. v. Aetna, Inc., Appeal No. 2022-2036 (Fed. Cir. Oct. 8, 2024)
In the Court’s only precedential patent opinion last week, a panel of the Federal Circuit granted appellant AlexSam a second chance to hold...more
Vascular Solutions LLC v. Medtronic, Inc., Appeal No. 24-1398 (Fed. Cir. Sept. 16, 2024)
In our Case of the Week, the Federal Circuit evaluated certain heavily litigated claims directed to guide catheters. The patents...more
Parkervision, Inc. v. Qualcomm Inc., Appeal Nos. 2022-1755, 2024-2221 (Fed. Cir. Sept. 6, 2024)
In this week’s Case of the Week, the Federal Circuit weighed in again on a 13-year-old patent dispute concerning Qualcomm’s...more
9/10/2024
/ Appeals ,
Daubert Standards ,
Intellectual Property Protection ,
Inter Partes Review (IPR) Proceeding ,
Intrinsic Evidence ,
Jury Verdicts ,
Patent Infringement ,
Patent Invalidity ,
Patent Litigation ,
Patent Trial and Appeal Board ,
Patents ,
Reversal
Wisconsin Alumni Research Foundation v. Apple Inc., Appeal Nos. 2022-1884, -1886 (Fed. Cir. Aug. 28, 2024)
In its only precedential patent decision last week, the Federal Circuit brought to a close a long-running dispute...more
Realtime Adaptive Streaming L.L.C. v. Sling TV, L.L.C., Appeal No. 2023-1035 (Fed. Cir. August 23, 2024)
In its only precedential patent decision this week, the Federal Circuit helped clarify which facts may be...more
8/27/2024
/ Appeals ,
Attorney's Fees ,
Exceptional Case ,
Inter Partes Review (IPR) Proceeding ,
Patent Invalidity ,
Patent Litigation ,
Patents ,
Precedential Opinion ,
Remand ,
Section 101 ,
Section 285